DNA fingerprinting of Pseudomonas aeruginosa (Pa) in cystic fibrosis patients: risk assessment of cross-colonisation in a CF revalidation centre Source: Eur Respir J 2002; 20: Suppl. 38, 208s Year: 2002
Achromobacter (A.) xylosoxidans in cystic fibrosis: prevalence and clinical relevanceSource: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005
DNA fingerprinting of pseudomonas aeruginosa in cystic fibrosis patients: risk assessment of cross-infection in a CF centre Source: Eur Respir J 2002; 20: Suppl. 38, 208s Year: 2002
Impact of Achromobacter xylosoxidans isolation on the respiratory function of adult patients with cystic fibrosis Source: ERJ Open Res, 5 (4) 00051-2019; 10.1183/23120541.00051-2019 Year: 2019
Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients Source: Eur Respir J 2006 Oct 01;28(4):740-747 Year: 2006
Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients Source: Eur Respir J 2008; 31: 822-829 Year: 2008
Molecular genetic characteristics of Pseudomonas aeruginosa strains isolated from children with cystic fibrosis in Moscow. Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021
Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006
Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre Source: Eur Respir J 2005; 25: 474-481 Year: 2005
Isolation of Achromobacter xylosoxidans from the respiratory secretions of patients with cystic fibrosis: frequency in the population and significance to the progression of lung disease Source: Eur Respir J 2005; 26: Suppl. 49, 402s Year: 2005
Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres Source: Eur Respir J 2013; 41: 1091-1100 Year: 2013
Cystic fibrosis patients and families support cross-infection measures Source: Eur Respir J 2004; 24: 449-452 Year: 2004
Cystic fibrosis infection with clonal strains of Pseudomonas aeruginosa: current knowledge and future management Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=105 Year: 2006
Pseudomonas aeruginosa transmission is infrequent in New Zealand cystic fibrosis clinics Source: Eur Respir J 2008; 32: 1583-1590 Year: 2008
The clinical impact of Pseudomonas aeruginosa eradication in bronchiectasis in a Dutch referral centre Source: Eur Respir J, 53 (4) 1802081; 10.1183/13993003.02081-2018 Year: 2019
Scedosporium species (Sspp) in patients with cystic fibrosis (CF): Implications for clinical practice Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010
Variability of ß-lactamase resistance Pseudomonas aeruginosa genes infecting patients with cystic fibrosis Source: Virtual Congress 2021 – Back to infection basics Year: 2021
LATE-BREAKING ABSTRACT: Pseudomonas aeruginosa strain prevalence, adaptation and diversification, during chronic lung infections of UK non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016
Cystic fibrosis: Achromobacter xylosoxidans colonized patients have more severe respiratory disease Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013
The identification of bacterial strains in specimens of adult cystic fibrosis patients Source: Eur Respir J 2004; 24: Suppl. 48, 49s Year: 2004